Baxter International Inc. and ScinoPharm Taiwan, Ltd., a global API manufacturer, have entered a strategic partnership to develop, manufacture and commercialize five injectable drugs for a range of cancer treatments, including lung cancer, multiple myeloma and breast cancer, as well as medication to treat nausea and vomiting associated with chemotherapy. Baxter also has the option to partner with ScinoPharm on as many as 15 additional injectable molecules. The companies will collaborate on pr...